Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Non-cash Items (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Non-cash Items for 3 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 96.62% to $10.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.1 million through Dec 2025, down 96.62% year-over-year, with the annual reading at $10.1 million for FY2025, 96.62% down from the prior year.
  • Non-cash Items hit $10.1 million in Q4 2025 for NewAmsterdam Pharma, roughly flat from $10.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $298.0 million in Q4 2024 to a low of $6.1 million in Q1 2024.
  • Historically, Non-cash Items has averaged $94.7 million across 3 years, with a median of $50.8 million in 2023.
  • Biggest YoY gain for Non-cash Items was 2895.97% in 2025; the steepest drop was 96.62% in 2025.
  • Year by year, Non-cash Items stood at $50.8 million in 2023, then soared by 486.62% to $298.0 million in 2024, then plummeted by 96.62% to $10.1 million in 2025.
  • Business Quant data shows Non-cash Items for NAMS at $10.1 million in Q4 2025, $10.1 million in Q3 2025, and $141.1 million in Q2 2025.